Zheng Bingyi, Wang Xueting, Guo Meizhai, Tzeng Chi-Meng
Translational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361005, China.
Int J Mol Sci. 2025 May 27;26(11):5131. doi: 10.3390/ijms26115131.
In recent decades, peptide-based therapeutics have undergone transformative advancements driven by breakthroughs in production, modification, and analytical technologies. Innovations in chemical and biological synthesis, coupled with novel design and delivery strategies, have systematically addressed historical limitations (e.g., poor stability and bioavailability). These advancements have facilitated the characterization and clinical translation of diverse natural and engineered peptides across therapeutic domains, including metabolic disorders, oncology, and infectious diseases. This review synthesizes critical developments in peptide drug discovery, production technologies, and clinical applications, while highlighting emerging challenges and opportunities. We further evaluate the therapeutic potential of peptides in addressing unmet medical needs and propose strategic directions to accelerate their integration into precision medicine paradigms.
近几十年来，基于肽的治疗药物在生产、修饰和分析技术方面取得了突破性进展，从而实现了变革性的进步。化学和生物合成方面的创新，以及新颖的设计和递送策略，系统地解决了以往的局限性（如稳定性和生物利用度差）。这些进展促进了各种天然和工程肽在包括代谢紊乱、肿瘤学和传染病在内的治疗领域的表征和临床转化。本综述总结了肽类药物发现、生产技术和临床应用方面的关键进展，同时强调了新出现的挑战和机遇。我们进一步评估了肽在满足未满足医疗需求方面的治疗潜力，并提出了战略方向，以加速其融入精准医学范式。
